Results 11 to 20 of about 1,677,176 (219)
European Standard Clinical Practice Guideline and EXPeRT Recommendations for the Diagnosis and Management of Gastroenteropancreatic Neuroendocrine Neoplasms in Children and Adolescents
Pediatric Blood &Cancer, EarlyView.ABSTRACT
Pediatric gastroenteropancreatic neuroendocrine neoplasms (GEP‐NENs) are extremely rare and clinically heterogeneous. Management has largely been extrapolated from adult practice. This European Standard Clinical Practice Guideline (ESCP), developed by the EXPeRT network in collaboration with adult NEN experts, provides (adult) evidence ...Michaela Kuhlen, Calogero Virgone, Antje Redlich, Michael Abele, Ricardo Lopez‐Almaraz, Tal Ben‐Ami, Ewa Bien, Gianni Bisogno, Maja Mazic Cesen, Andrea Ferrari, Malgorzata A. Krawczyk, Yves Reguerre, Dominik T. Schneider, Ines B. Brecht, Charlotte Rigaud, Bilgehan Yalcin, Rainer Claus, Christian Vokuhl, Constantin Lapa, Jörg Fuchs, Segolene Hescot, Thomas Walter, Julien Hadoux, Daniel Orbach +23 morewiley +1 more sourceCPX‐351 in High‐Risk Relapsed Pediatric Acute Leukemia: Real‐World Phase 1 Data Establishing the FDA‐Approved Dose
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background/Objectives
Outcomes for pediatric relapsed/refractory (R/R) acute myeloid leukemia (AML) remain dismal. CPX‐351, a liposomal formulation of cytarabine and daunorubicin, may have less off‐target toxicities than traditional chemotherapies and has shown improved outcomes for adults with newly diagnosed therapy‐related AML.Jonathan D. Bender, Lauren Pommert, Lori R. Backus, Andrea Bidwell, Courtney Blank, Erin H. Breese, Karen C. Burns, Adam Lane, Lynn H. Lee, Benjamin Mizukawa, Robin E. Norris, Maureen M. O'Brien, Daniel Peck, Christine Phillips, Thomas D. Ryan, Jennifer Young, Michael Absalon, John P. Perentesis +17 morewiley +1 more sourceNovel Genetic Risk Factor Identified for L‐Asparaginase‐Induced Pancreatitis in Pediatric Patients With Cancer
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background
L‐asparaginase is a critical component in treatment protocols for pediatric acute lymphoblastic leukemia. Acute pancreatitis reactions can necessitate delays and, in some cases, discontinuation of L‐asparaginase, which compromises outcomes.Edward J. Raack, Wan‐Chun Chang, Miguel Cordova‐Delgado, Spencer J. Anderson, Jessica N. Trueman, Erika N. Scott, Catrina M. Loucks, Shahrad R. Rassekh, Gabriella S. S. Groeneweg, Michelle Higginson, Kathy Li, Fudan Miao, Derek Yau, Donna Johnston, Mounira Ibrahim, Maja Krajinovic, Thai Hoa Tran, Jessica Tewfik, Jean‐François Bussières, Thaïna‐Rafi Jean‐Baptiste, Denis Lebel, Lucie Pecheux, Bina Gyawali, Gregory Guilcher, Gesche Riabowol, Geert ’t Jong, Michelle Staub, Geoff Cuvelier, Kathleen Felton, Sara Khalaj, Michael Rieder, Awatif Abuzgaia, Tamorah Lewis, Himal Ghimire, Paul Nathan, Kerry Goralski, Ketan Kulkarni, Zara Forbrigger, Colin J. D. Ross, Bruce C. Carleton +39 morewiley +1 more sourceOutcomes and Surgical Management of Malignant Rhabdoid Tumor of the Kidney: A Report From the Pediatric Surgical Oncology Research Collaborative
Pediatric Blood &Cancer, EarlyView.ABSTRACT Purpose
Malignant rhabdoid tumor of the kidney (MRTK) is a rare, aggressive tumor seen in young children. The optimal timing of resection for locally advanced tumors is not well‐defined. The purpose of this study is to evaluate modern oncologic outcomes and the impact of surgical timing. Methods
A multicenter retrospective review was performed Hannah N. Rinehardt, Elisabeth T. Tracy, Anghela Paredes, Catherine Beckhorn, Harold J. Leraas, Joseph Fusco, Katlyn G. McKay, Nelly‐Ange T. Kontchou, Zachary J. Kastenberg, David W. Hoyt, Jonathan Roach, Emily K. Myers, Nicholas G. Cost, Bhargava Mullapudi, Charles R. Marchese, Amanda R. Jensen, Timothy B. Lautz, Michela Carter, Roshni Dasgupta, John Lundstedt, Joseph G. Brungardt, Lindsay Talbot, Andrew M. Davidoff, Andrew J. Murphy, Jennifer H. Aldrink, Sara Mansfield, Nelson Piche, Annie Le‐Nguyen, Dave R. Lal, Brian T. Craig, Jennifer M. Schuh, Barrett P. Cromeens, Sindhu Mannava, Shannon Castle, Adriana Lopez, Kelsey Mello, Joshua Short, Robin T. Petroze, Shay Rajavel, Grace R. Thompson, Peter Mattei, David H. Rothstein, Elizabeth Fialkowski, Kathryn Fowler, Nathan Martchenke, Barrie S. Rich, Richard D. Glick, Erin G. Brown, Kathleen Doyle, Paige Abril, Natashia Seemann, Jacob Davidson, Claire A. Wilson, Hau D. Le, Devashish Joshi, Michael Stellon, Tamer Ahmed, Alexandra Dimmer, Peter F. Ehrlich, Maya Hammoud, Keyonna Williams, Christa N. Grant, Merit Gorgy, Stephanie F. Polites, Julia Debertin, Danielle B. Cameron, Alyssa Stetson, Eugene S. Kim, William G. Lee, Aaron Barkhordar, Mary Austin, Brian A. Coakley, Anastasia Kahan, Joseph T. Murphy, Michael Pitonak, Chloé Boehmer, Marcus M. Malek +76 morewiley +1 more sourceMYCN Amplification in RB1‐Inactivated Retinoblastoma: Association With High‐Risk Features
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background
MYCN amplification occurs in a subset of retinoblastoma cases, both with and without RB1 inactivation. It has been suggested that retinoblastomas with MYCN amplification represent a distinct entity with more aggressive clinical behavior.Kyriaki Papaioannou, Regina Kubica, Karen Fischhuber, Jasmin Beygo, Madlen Reschke, Petra Ritter‐Sovinz, Eva Biewald, Petra Ketteler, Dietmar Lohmann, Deniz Kanber +9 morewiley +1 more sourceClinical Insights Into Hypercalcemia of Malignancy in Childhood
Pediatric Blood &Cancer, EarlyView.ABSTRACT
Hypercalcemia of malignancy (HCM) is a rare but life‐threatening metabolic emergency in children that occurs in less than 1% of pediatric cancer cases, with a reported incidence ranging from 0.4% to 1.0% across different studies. While it is observed in 10%–20% of adult malignancies, pediatric HCM remains relatively uncommon.Hüseyin Anıl Korkmazwiley +1 more sourceAdherence to Protocol Recommendations for Children With Wilms Tumour in Two Consecutive Studies in the United Kingdom and Ireland—Does Variation Matter?
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background and Aims
Wilms tumour (WT) has excellent event‐free and overall survival (OS). However, small differences exist between countries participating in the same international study. This led us to examine variation in adherence to protocol recommendations as a potential contributing factor.Suzanne Tugnait, R. Al‐Saadi, A. Lopez‐Cortes, K. Dzhuma, M. Oostveen, J. Brok, S. Irtan, M. Weeks, J. Bate, S. Baker, R. Williams, M. Powis, D. Saunders, O. Olsen, T. Watson, S. Shelmerdine, S. Vaidya, L. Howell, C. Duncan, G. M. Vujanic, C. Stiller, G. P. Balchin, T. Chowdhury, K. Pritchard‐Jones +23 morewiley +1 more sourceEvaluating the Utility of Paired Tumor and Germline Targeted DNA Sequencing for Pediatric Oncology Patients: A Single Institution Report
Pediatric Blood &Cancer, EarlyView.ABSTRACT Objective
To evaluate the diagnostic yield and utility of universal paired tumor–normal multigene panel sequencing in newly diagnosed pediatric solid and central nervous system (CNS) tumor patients and to compare the detection of germline pathogenic/likely pathogenic variants (PV/LPVs) against established clinical referral criteria for cancer ...Natalie Waligorski, Rebecca Ronsley, Shannon M. Stasi, Jeffrey Stevens, Erin R. Rudzinski, Christina M. Lockwood, Sarah E. S. Leary, Bonnie L. Cole, Michelle A. Ting, Vera Paulson +9 morewiley +1 more source